Home/Pipeline/LAT8881

LAT8881

Lumbar Radicular Pain (Sciatica)

Phase 1bCompleted; safety in >700 patients

Key Facts

Indication
Lumbar Radicular Pain (Sciatica)
Phase
Phase 1b
Status
Completed; safety in >700 patients
Company

About Lateral Pharma

An Australian biotech developing first-in-class LanCL-targeting therapies for neuropathic pain, neurodegeneration, and healthy ageing.

View full company profile

Other Lumbar Radicular Pain (Sciatica) Drugs

DrugCompanyPhase
SX600Frenelle PharmaPhase 2